PKI 166 hydrochloride

Key Product Details

Product Description

PKI 166 hydrochloride is a potent EGFR-kinase inhibitor (IC₅₀ = 0.7 nM). Displays >3000-fold selectivity against a panel of serine/threonine kinases. Reduces metastasis and angiogenesis in a mouse model of pancreatic cancer. Antihypertensive and orally bioavailable.

Product Specifications for PKI 166 hydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for PKI 166 hydrochloride

The following data is based on the product molecular weight 366.84.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.73 mL	13.63 mL	27.26 mL
5 mM	0.55 mL	2.73 mL	5.45 mL
10 mM	0.27 mL	1.36 mL	2.73 mL
50 mM	0.05 mL	0.27 mL	0.55 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ulu Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. J.Pharmacol.Exp.Ther. 2013 PMID: 23528611
• Kaspersen Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena. Bioorg.Chem. 2012 PMID: 22832269
• Bruns Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 PMID: 10850439

Product Documents for PKI 166 hydrochloride